Josep Lluis Parra
Autonomous University of Barcelona
6 Papers
47 Citations
Josep Lluis Parra is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Lapatinib & Cancer. The author has an hindex of 5, co-authored 6 publications. Previous affiliations of Josep Lluis Parra include Hebron University.
Chat about Author
Papers
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Violeta Serra,Benjamin Markman,Maurizio Scaltriti,Pieter Johan Adam Eichhorn,Vanesa Valero,Marta Guzman,Maria Luisa Botero,Elisabeth Llonch,Francesco Atzori,Serena Di Cosimo,Michel Maira,Carlos Garcia-Echeverria,Josep Lluis Parra,Joaquín Arribas,José Baselga +14 more
TL;DR: NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.
780
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, PreventsPI3K Signaling and Inhibitsthe Growth of Cancer Cellswith Activating PI3K Mutations
Violeta Serra,Ben Markman,Maurizio Scaltriti,Vanesa Valero,M. Guzman,Maria Luisa Botero,Elisabeth Llonch,Francesco Atzori,Michel Maira,Carlos Garcia-Echeverria,Josep Lluis Parra,Joaquín Arribas +11 more
- 01 Jan 2008
TL;DR: NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR), was shown to have antiproliferative and antitumoral activity in cancer cells with both wild type and mutated p110-A as mentioned in this paper.
705
Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
Violeta Serra,Ana Vivancos,Xose S. Puente,Enriqueta Felip,Daniel Silberschmidt,Ginevra Caratu,Josep Lluis Parra,Leticia De Mattos-Arruda,Judit Grueso,Javier Hernández-Losa,Joaquín Arribas,Ludmila Prudkin,Paolo Nuciforo,Maurizio Scaltriti,Joan Seoane,José Baselga +15 more
TL;DR: In this article, the authors reported the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations.
51
Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial
M Scaltriti,Paolo Nuciforo,Ian Bradbury,Jeff Sperinde,Violeta Serra,Josep Lluis Parra,Ludmila Prudkin,Nadia Harbeck,Lajos Pusztai,Catherine E. Ellis,H Eidtmann,Joaquín Arribas,M.J. Piccart,J. Baselga +13 more
TL;DR: increasing HER2 protein expression correlated with increased benefit of adding L to T compared to T alone, suggesting that, in the neoadjuvant setting, the association between p95HER2 expression and response to anti-HER2 therapy is likely a consequence of the correlation between p 95HER2 and total HER2 levels.
3
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Maurizio Scaltriti,Paolo Nuciforo,Ian Bradbury,Jeff Sperinde,Dominique Agbor-Tarh,Christine Campbell,Ahmed Chenna,John Winslow,Violeta Serra,Josep Lluis Parra,Ludmila Prudkin,Jose Jimenez,Claudia Aura,Nadia Harbeck,Lajos Pusztai,Catherine E. Ellis,Holger Eidtmann,Joaquín Arribas,Javier Cortes,Evandro de Azambuja,Martine Piccart,José Baselga +21 more
TL;DR: Investigating whether the levels of p95HER2 and HER2 can predict response to anti-HER2 therapy in patients with breast cancer found high levels of these markers were predictive for pCR, especially in the hormone receptor (HR)–positive subset of patients.